Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of cancer immunotherapy drugs. The company offers Gene Mediated Cytotoxic Immunotherapy technology-based drugs that are designed to work with radiation, chemotherapy, and surgery to eradicate residual tumor cells that could lead to recurrence or metastases. Its product candidates include CAN-2409, an off-the-shelf adenovirus product candidate, for the treatment of localized, primary prostate cancer and therapy for pancreatic cancer; and CAN-3110, its HSV product candidate, has been engineered for enhanced specificity and tumor cell killing, while minimizing toxicity on healthy tissue and indicated for the treatment of recurrent high-grade glioma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was founded in 1999 and is based in Needham, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: candeltx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/20/2025 | $25.00 | Buy | Citigroup |
| 2/19/2025 | $20.00 | Buy | Canaccord Genuity |
| 2/7/2025 | $15.00 | Buy | BofA Securities |
| 12/2/2022 | $11.00 | Buy | H.C. Wainwright |
| 11/19/2021 | $18.00 | Outperform | BMO Capital |
| 8/23/2021 | $9.00 | Buy | UBS |
| 8/23/2021 | $22.00 | Buy | Jefferies |
| 8/23/2021 | $15.00 | Outperform | Credit Suisse |
4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
4/A - Candel Therapeutics, Inc. (0001841387) (Issuer)
4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)
SC 13G/A - Candel Therapeutics, Inc. (0001841387) (Subject)
SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)
SC 13D - Candel Therapeutics, Inc. (0001841387) (Subject)
SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)
8-K - Candel Therapeutics, Inc. (0001841387) (Filer)
144 - Candel Therapeutics, Inc. (0001841387) (Subject)
144 - Candel Therapeutics, Inc. (0001841387) (Subject)
S-8 - Candel Therapeutics, Inc. (0001841387) (Filer)
10-K - Candel Therapeutics, Inc. (0001841387) (Filer)
8-K - Candel Therapeutics, Inc. (0001841387) (Filer)
8-K - Candel Therapeutics, Inc. (0001841387) (Filer)
SCHEDULE 13G - Candel Therapeutics, Inc. (0001841387) (Subject)
SCHEDULE 13G/A - Candel Therapeutics, Inc. (0001841387) (Subject)
SCHEDULE 13G/A - Candel Therapeutics, Inc. (0001841387) (Subject)
4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
NEEDHAM, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Elizabeth M. Jaffee, M.D., to the Company's Research Advisory Board (RAB). Dr. Jaffee, an internationally recognized expert in cancer immunology and pancreatic cancer, brings her extensive expertise to the RAB, which is important in light of the Company's focus on borderline resectable pancreatic cancer. Dr. Jaffee currently serves as the Dana and Albert "Cubby" Broccoli Professor of Oncology, Deputy Dire
MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors ("Board"), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, transformation, and strategic M&A transactions, including as former Chairman and CEO of Bausch + Lomb, Bausch Health and Perrigo and as a director of SparingVision and Candel Therapeutics. He brings bro
NEEDHAM, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the Company is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitaliza
NEEDHAM, Mass., June 08, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced the appointment of Nicoletta Loggia, PhD, RPh, to the Company's Board of Directors (Board) effective June 7, 2023. "We are pleased to welcome Nicoletta as a new member of Candel's Board," said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer (CEO) of Candel. "Her wealth of strategic and hands-on industry experience in drug development and manufacturing makes her an important addition to our Board as we advance our late-
Discovery collaboration underway with Center for Cellular Immunotherapies Lab at University of Pennsylvania to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy Candidates in Solid Tumor ModelsUpcoming clinical data presentations at SITC and SNO Annual MeetingsVirtual R&D Day on December 6, 2022, with Candel leadership and renowned oncology experts NEEDHAM, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on helping patients fight cancer with viral immunotherapies, today reported financial results for the third quarter ended September 30, 2022 and provided a cor
NEEDHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. "2022 is off to a great start as we continue to advance our late-stage pipeline of novel oncolytic viral immunotherapies for cancer," said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. "Today, we are well positioned for major catalysts over the next 12 months, namely multiple clinical data readouts across our
NEEDHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (NASDAQ:CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Seshu Tyagarajan Ph.D., RAC, has been named as the company's Chief Technical and Development Officer. Dr. Tyagarajan brings to Candel over two decades of technical, manufacturing and development experience in biologics and cell and gene therapies (CGT). Dr. Tyagarajan joins the company from Novartis, where she was most recently Executive Director and Global Head, Late Stage CMC Strategy for CGT. She was a member of the Novartis leadership team responsible for building a CGT pipelin
NEEDHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (NASDAQ:CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Francesca Barone, M.D., Ph.D., has been named as the company's Chief Scientific Officer. Dr. Barone brings more than 20 years of experience in immunology, experimental medicine, and innovative drug development to help bring important new therapeutics to the clinic. Dr. Barone was previously Candel's Vice President, Head of Research having joined the company in November 2020. Prior to Candel, Dr. Barone was Head of Experimental Medicine at Kintai Therapeutics and Senda Biosciences, t
NEEDHAM, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (NASDAQ:CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced it has appointed Mace L. Rothenberg, MD, as a senior advisor to its President and Chief Executive Officer, Paul Peter Tak, MD, PhD, FMedSci. Dr. Rothenberg, an industry veteran with more than 30 years of experience across government, academia and industry, will help support the company's continued growth and acceleration. "I am delighted to welcome Mace as an advisor to Candel Therapeutics to further strengthen our team," said Dr. Tak. "His impressive background as a physician-executive
Citigroup initiated coverage of Candel Therapeutics with a rating of Buy and set a new price target of $25.00
Canaccord Genuity initiated coverage of Candel Therapeutics with a rating of Buy and set a new price target of $20.00
BofA Securities initiated coverage of Candel Therapeutics with a rating of Buy and set a new price target of $15.00
H.C. Wainwright initiated coverage of Candel Therapeutics with a rating of Buy and set a new price target of $11.00
BMO Capital initiated coverage of Candel Therapeutics with a rating of Outperform and set a new price target of $18.00
UBS initiated coverage of Candel Therapeutics with a rating of Buy and set a new price target of $9.00
Jefferies initiated coverage of Candel Therapeutics with a rating of Buy and set a new price target of $22.00
Credit Suisse initiated coverage of Candel Therapeutics with a rating of Outperform and set a new price target of $15.00
Positive topline data for CAN-2409 viral immunotherapy achieved primary endpoint by demonstrating statistically significant and clinically meaningful benefit when combined with radiation therapy for intermediate-to-high risk, localized prostate cancerThe safety profile of CAN-2409 was generally consistent with previous studies, with no new safety signals identifiedThe phase 3 clinical trial was conducted under a Special Protocol Assessment (SPA) with the FDA NEEDHAM, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients
Expects to announce clinical trial data from multiple oncology programs in the second half of 2023Extends cash runway into second quarter of 2024 NEEDHAM, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update. "Our 2022 achievements reaffirm our belief that using our viral immunotherapies to mobilize the patient's immune system to fight cancer represents a promising a
NEEDHAM, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update. "Candel remains on track to achieve several milestones in the second half of 2022," said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. "We are encouraged by the initial phase 2 clinical trial data for CAN-2409 in non-small cell lung cancer presented in June at ASCO. The data presented at ASCO showed an 87.5
NEEDHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the publication of a manuscript reporting the results of a phase 1b clinical trial exploring safety and tolerability of the combination of CAN-2409 plus prodrug (valacyclovir) and nivolumab, in addition to standard of care (neurosurgery, radiotherapy, and temozolomide), in patients with newly diagnosed high-grade glioma. The study, which includes evidence of clinical activity and extensive biomarker analysis, has been published
Experimental treatment with CAN-2409 was associated with a median overall survival (mOS) of 24.5 months in patients with advanced NSCLC who had an inadequate response to ICI treatment, failed several chemotherapy regimens, and presented with multiple negative prognostic factors at enrollment (90% of the patients had stage IV disease, most patients had low or undetectable PDL-1 expression, > 90% were current or former smokers, and most patients had failed multiple lines of chemotherapy)mOS of 21.5 months was observed in patients with progressive disease at baseline despite ICI therapy (cohort 2), markedly exceeding mOS which has been reported in published literature for this population with s
NEEDHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, together with IDEA Pharma, a Division of SAI MedPartners (IDEA), a pioneering biopharmaceutical strategy consultancy, today announced a strategic commercial partnership. Under this agreement, IDEA will provide strategic commercial input throughout the development and commercialization process for Candel's lead asset, CAN-2409. This partnership comes at a pivotal time for Candel following positive phase 3 data for CAN-2409 in intermediate-to-hi
NEEDHAM, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Elizabeth M. Jaffee, M.D., to the Company's Research Advisory Board (RAB). Dr. Jaffee, an internationally recognized expert in cancer immunology and pancreatic cancer, brings her extensive expertise to the RAB, which is important in light of the Company's focus on borderline resectable pancreatic cancer. Dr. Jaffee currently serves as the Dana and Albert "Cubby" Broccoli Professor of Oncology, Deputy Dire
Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, localized prostate cancerRecently announced positive final data from randomized controlled phase 2a clinical trial of CAN-2409 in borderline resectable pancreatic ductal adenocarcinomaOn track to report biomarker and final overall survival data from open label phase 2a clinical trial per protocol analysis in non-small cell lung cancer (NSCLC) patients who received two administrations of CAN-2409, expected in Q1 2025On track to report biomarker and initial survival data from ongoing phase 1b trial evaluating multiple doses of CAN-3110 in patients with r
Positive final survival data after additional follow-up showed notable improvement in estimated median overall survival of 31.4 months after experimental treatment with CAN-2409 versus only 12.5 months in the control group in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC). Three of seven patients treated with CAN-2409 were still alive with survival of 66.0, 63.6 and 35.8 months after enrollment, respectively. Survival from the time of diagnosis for these patients was 73.5, 68.8, and 41.3 months, respectively. Survival observed in these patients is well beyond the expected median overall survival for pancreatic cancer with standard of care, suggesting a long ta
On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferencesOn track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025The Company expects that its cash and cash equivalents of approximately
NEEDHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. ("Candel") (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the closing of its previously announced underwritten public offering of 12,000,001 shares of its common stock at a price to the public of $6.00 per share and pre-funded warrants to purchase up to an aggregate of 3,333,333 shares of its common stock at a price to the public of $5.99 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.01 per shar
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. ("Candel") (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the pricing of an underwritten public offering of 10,000,001 shares of its common stock at a price to the public of $6.00 per share and pre-funded warrants to purchase up to an aggregate of 3,333,333 shares of its common stock at a price to the public of $5.99 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for e
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. ("Candel") (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the launch of an underwritten public offering of $80 million of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Candel. Candel also intends to grant the underwriters a 30-day option to purchase up to an additional $12 million of the shares of its common stock offered i